Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease.
Ontology highlight
ABSTRACT: Antibody therapies to prevent or limit filovirus infections have received modest interest in recent years, in part because of early negative experimental evidence. We have overcome the limitations of this approach, leveraging the use of antibody from nonhuman primates (NHPs) that survived challenge to filoviruses under controlled conditions. By using concentrated, polyclonal IgG antibody from these survivors, we treated filovirus-infected NHPs with multiple doses administered over the clinical phase of disease. In the first study, Marburg virus (MARV)-infected NHPs were treated 15 to 30 min postexposure with virus-specific IgG, with additional treatments on days 4 and 8 postexposure. The postexposure IgG treatment was completely protective, with no signs of disease or detectable viremia. M
SUBMITTER: Dye JM
PROVIDER: S-EPMC3323977 | biostudies-literature | 2012 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA